Pomalidomide Krka | European Medicines Agency (EMA)

March 19, 2025

[ad_1]

Overview

Pomalidomide Krka is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow). It is used in combination with bortezomib (another cancer medicine) and dexamethasone (an anti-inflammatory medicine) in adults who have received at least one treatment including lenalidomide (another cancer medicine).

It is also used in combination with dexamethasone in adults who have received at least two prior therapies, including both lenalidomide and bortezomib, and whose disease has worsened.

Pomalidomide Krka contains the active substance pomalidomide and is a ‘generic medicine’. This means that Pomalidomide Krka contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Pomalidomide Krka is Imnovid. For more information on generic medicines, see the question-and-answer document here.

Treatment with Pomalidomide Krka must be started and supervised by a doctor experienced in treating multiple myeloma. The medicine can only be obtained with a prescription.

Pomalidomide Krka is available as capsules. It is taken daily in the first 2 weeks of 3-week treatment cycles, when given in combination with bortezomib and dexamethasone, and in the first 3 weeks of 4-week treatment cycles when given in combination with dexamethasone only.

Treatment with Pomalidomide Krka may need to be interrupted or stopped, or the dose may need to be reduced, if the disease gets worse or certain side effects occur. For more information about using Pomalidomide Krka, see the package leaflet or contact your doctor or pharmacist.

The active substance in Pomalidomide Krka, pomalidomide, is an immunomodulating agent. This means that it affects the activity of the immune system (the body’s natural defences). Pomalidomide works in a number of ways in multiple myeloma: it blocks the development of tumour cells, prevents the growth of blood vessels within tumours and also stimulates some specialised cells of the immune system to attack the tumour cells.

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Imnovid, and do not need to be repeated for Pomalidomide Krka.

As for every medicine, the company provided studies on the quality of Pomalidomide Krka. The company also carried out a study that showed that it is ‘bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

Because Pomalidomide Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The European Medicines Agency concluded that, in accordance with EU requirements, Pomalidomide Krka has been shown to have comparable quality and to be bioequivalent to Imnovid. Therefore, the Agency’s view was that, as for Imnovid, the benefits of Pomalidomide Krka outweigh the identified risks and it can be authorised for use in the EU.

Pomalidomide Krka received a marketing authorisation valid throughout the EU on 24 July 2024.

English (EN)
(136.55 KB – PDF)

First published: 01/08/2024Last updated: 24/09/2024

View

English (EN)
(810.45 KB – PDF)

First published: 01/08/2024

View

Product information

English (EN)
(495.48 KB – PDF)

First published: 01/08/2024Last updated: 19/03/2025

View

Latest procedure affecting product information:
N/0000252892

17/03/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(66.7 KB – PDF)

First published: 01/08/2024

View

English (EN)
(130.42 KB – PDF)

First published: 01/08/2024

View

Product details

Name of medicine: Pomalidomide Krka
Active substance: Pomalidomide
International non-proprietary name (INN) or common name: pomalidomide
Therapeutic area (MeSH): Multiple Myeloma
Anatomical therapeutic chemical (ATC) code: L04AX06

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Pomalidomide Krka in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

Pomalidomide Krka in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

[ad_2]

Source link

Overview

How is Pomalidomide Krka used?

How does Pomalidomide Krka work?

How has Pomalidomide Krka been studied?

What are the benefits and risks of Pomalidomide Krka?

Why is Pomalidomide Krka authorised in the EU?

What measures are being taken to ensure the safe and effective use of Pomalidomide Krka?

Other information about Pomalidomide Krka

Product information

Product details

Pharmacotherapeutic group

Therapeutic indication

LEAVE A REPLY Cancel reply